Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Enhanced Epilepsy Therapy with Genetic Analysis

12.03.2004


There are genetic differences between epilepsy patients that decide on whether medical treatment is successful or not. This is the result of a major study at the Vienna General Hospital. These new insights form the basis for an epilepsy therapy tailor-made for the needs of each individual patient. This study will be presented to the scientific community at the end of May at the largest European congress on epilepsy that will be taking place in Vienna this year.



As much as three percent of the population will contract epilepsy during the course of their lives. However, thanks to state-of-the-art medicines, two-thirds of all persons affected will be able to lead lives free of epileptic attacks, although one third respond less well to these drugs. These patients were the focus of a study with more than 630 test subjects carried out by the University Hospital of Neurology at the University Hospital of Neurology. This study was dedicated to unlocking the key to a phenomenon that has long since been known in this group of patients. Namely, why does the efficacy of drugs vary so strongly from one patient to the next? In the future, the results obtained from the study of Dr. Fritz Zimprich and his team will make it possible to make a dramatic improvement in the diagnosis of the efficacy of medical therapy.

We know that there are proteins that provide something akin to chemical detoxification and they are also to be found in the brain. These transport proteins ensure that potentially damaging substances are carried away from the cells. For a healthy organism, this protective mechanism makes a lot of sense. However, it can make it more difficult to treat diseased tissue with drugs because these proteins often transport medicines from the cells that are meant to cure them.


Dr. Zimprich, the head of the study, points out that "we have only known for a little while of the existence of these so-called multi-drug resistance proteins in the brain. We picked up on this by thinking that the known differences in drug efficacy from one epilepsy patient to another may be dependant upon how many of these proteins are active in the brain of each of these patients. In turn, the degree of activity may be impacted by minute variations in genes that code for these proteins."

There are at least two of these genes since every person has a set of two chromosomes. In this study, they compared the genetic sequence (symbolised by the letters A, C, G and T) of a very specific subsection of this pair of genes. The surprising finding was that five out of six of these epilepsy patients respond very poorly to drugs if the sequence is CGC on both subsections.

Dr. Zimprich provides further interpretation of the importance of these results: "Now, we are aware of the fact that this special section does not have a direct impact on the way the transport proteins functions. However, we think that this section may be something akin to an internal regulator that has a co-determining effect on how much of the protein is produced." In the future, we will be able to make reliable predictions on the efficacy of a medical therapy by analysing the pertinent gene sections of epilepsy patients. Beyond this, these insights will form the point of departure for future combined therapies where the transport proteins are switched off by additional therapeutic agents, thus augmenting the efficacy of traditional drugs.

Professor Christoph Baumgartner, the head of the Working Group for Clinical Epileptology, chairperson of the national organisational committee and Dr. Zimprich’s colleague, is especially proud that this study was concluded shortly before the 6th European Congress on Epileptology. "The European Congress of the International League against Epilepsy only takes place every two years and it will have its venue this year in Vienna from May 30 to June 3. This means that we will now be able to present this important research to the international scientific community in Vienna."

Till C. Jelitto | alfa
Further information:
http://www.epilepsyvienna2004.org

More articles from Health and Medicine:

nachricht Norovirus evades immune system by hiding out in rare gut cells
12.10.2017 | University of Pennsylvania School of Medicine

nachricht Flexible sensors can detect movement in GI tract
11.10.2017 | Massachusetts Institute of Technology

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Smart sensors for efficient processes

Material defects in end products can quickly result in failures in many areas of industry, and have a massive impact on the safe use of their products. This is why, in the field of quality assurance, intelligent, nondestructive sensor systems play a key role. They allow testing components and parts in a rapid and cost-efficient manner without destroying the actual product or changing its surface. Experts from the Fraunhofer IZFP in Saarbrücken will be presenting two exhibits at the Blechexpo in Stuttgart from 7–10 November 2017 that allow fast, reliable, and automated characterization of materials and detection of defects (Hall 5, Booth 5306).

When quality testing uses time-consuming destructive test methods, it can result in enormous costs due to damaging or destroying the products. And given that...

Im Focus: Cold molecules on collision course

Using a new cooling technique MPQ scientists succeed at observing collisions in a dense beam of cold and slow dipolar molecules.

How do chemical reactions proceed at extremely low temperatures? The answer requires the investigation of molecular samples that are cold, dense, and slow at...

Im Focus: Shrinking the proton again!

Scientists from the Max Planck Institute of Quantum Optics, using high precision laser spectroscopy of atomic hydrogen, confirm the surprisingly small value of the proton radius determined from muonic hydrogen.

It was one of the breakthroughs of the year 2010: Laser spectroscopy of muonic hydrogen resulted in a value for the proton charge radius that was significantly...

Im Focus: New nanomaterial can extract hydrogen fuel from seawater

Hybrid material converts more sunlight and can weather seawater's harsh conditions

It's possible to produce hydrogen to power fuel cells by extracting the gas from seawater, but the electricity required to do it makes the process costly. UCF...

Im Focus: Small collisions make big impact on Mercury's thin atmosphere

Mercury, our smallest planetary neighbor, has very little to call an atmosphere, but it does have a strange weather pattern: morning micro-meteor showers.

Recent modeling along with previously published results from NASA's MESSENGER spacecraft -- short for Mercury Surface, Space Environment, Geochemistry and...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

World Health Summit 2017: International experts set the course for the future of Global Health

10.10.2017 | Event News

Climate Engineering Conference 2017 Opens in Berlin

10.10.2017 | Event News

Conference Week RRR2017 on Renewable Resources from Wet and Rewetted Peatlands

28.09.2017 | Event News

 
Latest News

A single photon reveals quantum entanglement of 16 million atoms

16.10.2017 | Physics and Astronomy

The melting ice makes the sea around Greenland less saline

16.10.2017 | Earth Sciences

On the generation of solar spicules and Alfvenic waves

16.10.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>